Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Vivo Capital Closes Latest US-China PE Fund at $635 Million

publication date: Sep 12, 2018

Vivo Capital, a US-China healthcare investment firm, closed a new private equity fund at an oversubscribed $635 million. The Vivo Opportunity Fund will invest in US and China small to mid-cap public life sciences companies with novel products in development. Vivo raised $750 million for its previous PE fund in 2015, and it closed a $100 million venture capital fund in 2016. The firm, which has offices in Palo Alto, Beijing, Shanghai and Taipei, now has $2.2 billion in total funds under management. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events


China Showcase 2020

San Francisco, USA

January 12, 2020

ChinaBio Partnering Forum 2020

Suzhou, China

May 6-7, 2020

Other Events


Shanghai, China

November 18-20, 2019